Large-cap Consumer Discretionary company Kenvue has moved 0.8% so far today on a volume of 14,191,497, compared to its average of 23,120,250. In contrast, the S&P 500 index moved 0.0%.
Kenvue trades -12.34% away from its average analyst target price of $23.67 per share. The 12 analysts following the stock have set target prices ranging from $20.0 to $27.0, and on average have given Kenvue a rating of buy.
Anyone interested in buying KVUE should be aware of the facts below:
-
Kenvue has moved -23.5% over the last year, and the S&P 500 logged a change of 15.0%
-
Based on its trailing earnings per share of 0.57, Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 36.4 while the S&P 500 average is 15.97
-
KVUE has a forward P/E ratio of 16.3 based on its forward 12 month price to earnings (EPS) of $1.27 per share
-
The company has a price to earnings growth (PEG) ratio of 11.04 — a number near or below 1 signifying that Kenvue is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.65 compared to its sector average of 4.24
-
Kenvue Inc. operates as a consumer health company worldwide.
-
Based in Skillman, the company has 22,200 full time employees and a market cap of $39.73 Billion. Kenvue currently returns an annual dividend yield of 1.0%.